l advantages of VERU-111, potential for market and indication expansion Preclinical studies presented by Veru, showed a few advantages compared to Docetaxel. Oral administration of VERU-111 shows comparable tumor inhibition with IV administered Docetaxel in PC3 prostate cancer cell xenograft model. In a